Stem-like Cells in Bladder Cancer Cell Lines with Differential Sensitivity to Cisplatin

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 733-738

  Falso, Miranda J Sarachine ^a   Buchholz, Bruce A ^a   White, Ralph W Devere ^b  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aldehyde dehydrogenase; Bladder cancer; Cell lines; Cisplatin; Stem like cells; T24; TCCSUP

Indexed keywords

ALDEHYDE DEHYDROGENASE; CISPLATIN;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASTIC STEM CELLS; URINARY BLADDER NEOPLASMS;

EID: 84858790386     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet 374: 239-249, 2009.
2. Stein JP and Skinner DG: Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 24: 296-304, 2006. (Pubitemid 44143761)
3. Agarwal N and Hussain M: Management of bladder cancer, current and emerging strategies. Drugs 69: 1173-1187, 2009.
4. Shah JB, McConkey DJ and Dinney CPN: New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 17: 2608-2612, 2011.
5. Hanahan D and Weinberg B: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
6. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspective on current studies and future directions: AACR workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006. (Pubitemid 44623625)
7. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM and Smith C: Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96: 9118-9123, 1999. (Pubitemid 29374717)
8. Sladek NE: Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17: 7-23, 2003.
9. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ and McDonnell DP: Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 103: 11707-11712, 2006. (Pubitemid 44182515)
10. Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR and Mohuczy D: Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroxycyclophosphamide and acetaldehyde. J Pharm Exp Ther 312: 339-345, 1998.
11. + human breast cancer cells. Breast Cancer Res Treat, 2011.
12. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RCM and van der Pluijm G: High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70: 5163-5173, 2010.
13. Jiang F, Qiu Q, Khanna A, Todd NW, Deppak J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338, 2009.
14. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y and Tsujiuchi T: Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24: 501-505, 2010.
15. Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA and Loeb DM: High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLOS One 5: e13943, 2010.
16. Wang L, Park P, Zhang H, La Marca F and Lin C: Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128: 294-303, 2011.
17. Vinall RL, Ripoll AZ, Pan CX and Devere White RW: MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of P53-Rb pathway status. Int J Cancer, 2011.
18. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA and Jiang F: Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomark Prev 19: 327-337, 2010.
19. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti, Jr. J, Chang HY, van de Rijn M, Shortliffe L and Weissman IL: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Adad Sci USA 106: 14016-14021, 2009.
20. - metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120, 2008.
21. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang Z and Keller ET: ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo 25: 69-76, 2011.
22. Crallan RA, Georgopoulos NT and Southgate J: Experimental models of human bladder carcinogenesis. Carcinogenesis 27: 374-381, 2006. (Pubitemid 43378894)
23. Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25, 2008.